Viking Therapeutics, Inc. (VKTX) Q3 2018 Earnings Results

Viking Therapeutics Misses on EPS, Stock Up 2.18%

Viking Therapeutics reported a loss of $0.11 per share, which was in line with expectations, although no revenue figures were disclosed. The stock rose by 2.18% following the earnings report, likely due to investor optimism about the company's ongoing clinical programs despite the lack of guidance. The absence of revenue data may have contributed to a cautious outlook among analysts.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.11	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized their commitment to ongoing clinical development. However, they did not offer any updates on future guidance.

Management did not provide specific guidance for the upcoming quarters.

The focus remains on advancing clinical programs.

Viking Therapeutics Misses on EPS, Stock Up 2.18%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Up 2.18%

Key numbers

Management commentary